Colorectal cancer
Conditions
Interventions
None:None
Sponsors
The Sixth Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
19 Years to 82 Years
Inclusion criteria
Inclusion criteria: 1. The patient was diagnosed with metastatic colorectal cancer and had no other tumors; 2. The patient was receiving bevacizumab in combination with other chemotherapy drugs; 3. The patient had not received VEGF inhibitor treatment before; 4. The patient used at least 3 courses of bevacizumab.
Exclusion criteria
Exclusion criteria: 1. With other tumors at the same time; 2. With other uncontrollable systemic diseases; 3. Previously treated with other VEGF inhibitors; 4. Patients received bevacizumab less frequently 3 times.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure;Overall survival;Progress-free survival;Blood pressure from 2 months before treatment to 6 months after treatment, or before treatment with other VEGF inhibitors and other pressors;The use of bevacizumab, atropine, irinotecan and antihypertensive drugs; | — |
Countries
China
Contacts
Public ContactZhuoling Zheng
The Sixth Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed